Definition
Thrombospondin 1 (TSP‑1) is a secreted, multidomain extracellular matrix glycoprotein that participates in cell‑cell and cell‑matrix interactions, modulating processes such as angiogenesis, platelet aggregation, wound healing, inflammation, and activation of latent transforming growth factor‑β (TGF‑β).
Overview
Thrombospondin 1 is the prototypical member of the thrombospondin family, a group of secreted proteins distinguished by a conserved C‑terminal globular domain. First isolated from platelet α‑granules, TSP‑1 is produced by a variety of cell types, including endothelial cells, fibroblasts, smooth‑muscle cells, macrophages, and certain tumor cells. In physiological contexts, it functions as an anti‑angiogenic factor, a regulator of extracellular matrix organization, and a modulator of immune responses. Pathologically, altered expression of TSP‑1 has been linked to cardiovascular disease, fibrotic disorders, and tumor progression.
Etymology / Origin
The name combines the Greek prefix thrombo‑, meaning “clot” or “thrombus,” reflecting its initial identification in platelet clotting components, with ‑spondin, derived from the Greek verb spondē (“to bind” or “to weave”), referencing its role in mediating adhesive interactions between cells and the extracellular matrix.
Characteristics
| Feature | Description |
|---|---|
| Gene | Encoded by the THBS1 gene located on chromosome 15q14. |
| Structure | Forms a homotrimer (~450 kDa total), each subunit comprising several distinct domains: an N‑terminal heparin‑binding domain, properdin‑like type I repeats, epidermal growth factor‑like type II repeats, calcium‑binding type III repeats, and a C‑terminal globular domain. |
| Post‑translational modifications | N‑linked glycosylation and calcium binding are essential for stability and function. |
| Receptor interactions | Binds to multiple cell‑surface receptors, notably CD36, CD47, integrins (e.g., αvβ3), and low‑density lipoprotein receptor‑related protein‑1 (LRP1). |
| Biological activities | • Inhibits angiogenesis by interacting with CD36 and CD47, leading to endothelial cell apoptosis and suppression of nitric‑oxide signaling. • Activates latent TGF‑β via the latent‑associated peptide (LAP) binding site. • Promotes platelet aggregation through interaction with glycoprotein IIb/IIIa. • Modulates inflammation by influencing macrophage cytokine production. • Contributes to extracellular matrix assembly and remodeling. |
| Physiological regulation | Expression is up‑regulated by hypoxia, oxidative stress, cytokines (e.g., IL‑1β, TNF‑α), and transforming growth factor‑β itself, forming feedback loops. |
| Clinical relevance | Altered TSP‑1 levels are observed in atherosclerosis, diabetic retinopathy, pulmonary hypertension, systemic sclerosis, and various cancers, where it may serve as a prognostic biomarker or therapeutic target. |
Related Topics
- Thrombospondin family – includes Thrombospondin‑2, -3, -4, and -5, each sharing structural motifs but differing in tissue distribution and function.
- Extracellular matrix (ECM) – the network of macromolecules that provides structural and biochemical support to cells; TSP‑1 is a key ECM component.
- Angiogenesis – the formation of new blood vessels; TSP‑1 is a potent endogenous inhibitor.
- Platelet activation – TSP‑1 is released from platelet α‑granules during clot formation and contributes to aggregation.
- CD36 and CD47 receptors – cell‑surface proteins that mediate many of TSP‑1’s anti‑angiogenic and immunomodulatory effects.
- Transforming growth factor‑β (TGF‑β) activation – TSP‑1 facilitates conversion of latent TGF‑β to its active form, influencing fibrosis and immune regulation.
- Integrins – heterodimeric receptors that bind various ECM proteins, including TSP‑1, affecting cell adhesion and signaling.
- Diseases linked to TSP‑1 dysregulation – cardiovascular disease, cancer, chronic inflammatory and fibrotic conditions.